It inhibits endothelial cell migration and angiogenesis as well as cancer cell migration and metastases via CD44-dependent mechanisms.31,32 A recently completed Phase I clinical trial in patients with ovarian cancer and other solid tumors indicated a good safety profile, supporting further clinical studies.33 ALM201 was awarded orphan drug status by the FDA as a clinical candidate for the development of new drugs toward high-grade serious ovarian carcinomas.32 Here, CD44 is linked to ovarian carcinoma.